

**Supplement to:**

Phase-3 Dose Selection of Marzeptacog Alfa (Activated) Informed by Population  
Pharmacokinetic Modeling: A Novel Hemostatic Drug

Alan Faraj<sup>1</sup>, Tom Knudsen<sup>2</sup>, Shraddha Desai<sup>2</sup>, Linda Neuman<sup>2</sup>, Grant E. Blouse<sup>2</sup>, Ulrika S.H.  
Simonsson<sup>1\*</sup>

**Affiliations:**

<sup>1</sup>Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

<sup>2</sup>Catalyst Biosciences, South San Francisco, CA, USA




Figure S2. Visual predictive checks of the final population PK model on log scale for different dose levels following SC dosing. The solid and dashed lines are the median and, 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles of the observed data, respectively. The shaded areas (top to bottom) are the 95% confidence intervals of the 97.5<sup>th</sup> (light grey), median (dark grey) and 2.5<sup>th</sup> (light grey) percentiles of the simulated data. Open circles are observation points. The 30 µg/kg dose group had two observations at later time points but the VPC is cut for readability.